🟢 80/100

This product is generally safe

  • Niacin: 400mg is 11.4× the Tolerable Upper Intake Level (35mg)
  • 100% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 400mg is 11.4× the Tolerable Upper Intake Level (35mg)

Label Data

1 Capsule(s) Serving Size
Vitamin Product Type
100% Evidence Coverage

Supplement Facts — Evidence Check

400 mg (2000% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 11.4× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 400mg UL 35mg
100 mg
📊 Market median: 550.0mg (217 products) 📚 29 studies (Tier A: 0, B: 5)
This product: 100mg

Other Ingredients

Gelatin May contain one or more of the following

Label Claims — Verification

Nutrient
All Other
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: As a dietary supplement, adults take one capsule, one (1) to two (2) times daily with meals, or as directed by a health care professional.

⚠️ Warnings & Precautions

Keep out of reach of children.

🧪 Formulation Notes

Niacin No-Flush 400 mg of Vitamin B-3 as Inositol Hexanicotinate

Contains No Added sugar, salt, dairy, yeast, wheat, corn, soy, preservatives, artificial colors or flavors.

Additional Information

Store in a cool, dry place and away from direct light.

QUALITY AND POTENCY GUARANTEED

"We Make It Better..."

#10115

Our Niacin No-Flush will not cause the flush that is commonly associated with niacin use. It is derived from the finest Inositol Hexanicotinate available.

Product Details

DSLD Entry Date 2013-04-25
Product Type Vitamin
Form Capsule
DSLD ID 19009
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →